Mereo BioPharma Stock Soars 11.39% on Bullish Sentiment

Mereo Biopharma's stock price surged 11.39% in pre-market trading on March 27, 2025, indicating a strong bullish sentiment among investors.

Mereo BioPharma Group has maintained its Overweight rating and a $7.00 price target from Cantor Fitzgerald. This rating reflects the analysts' confidence in the company's potential for growth and profitability.

JPMorgan has initiated coverage on Mereo BioPharma with an Overweight rating, citing an attractive entry point for investors. The firm's analysts believe that the biopharma company has significant upside potential, making it a compelling investment opportunity.

In its full-year 2024 financial report, Mereo BioPharma highlighted a year of focused execution and strategic advancement. The company's lead programs have made significant progress towards key milestones, positioning it for future success.